Get started
Author

Antônio José Tibúrcio Alves

Observed names: A J T Alves Jr, A J T Alves Junior, A J Tiburcio Alves Junior, A.J.T. Alves, A.J.T. Alves Junior, Antonio Alves, Antonio Jose Tiburcio ALVES JUNIOR, Antonio Jose Tiburcio Alves, Antonio Jose Tiburcio Alves Junior, Antonio Jose Tibúrcio Alves Junior, Antonio José Tiburcio ALVES JR, Antonio José Tiburcio Alves, Antonio José Tiburcio Alves Junior, Antonio José Tibúrcio Alves, Antonio José Tibúrcio Alves Junior, Antônio José Tibúrcio Alves Junior, Antônio José Tibúrcio Alves Júnior
ORCID: 0000-0002-6795-8526
Observed ORCID: 0000-0002-6795-8526
OpenAlex ID: A5019535971
Long-term effectiveness and safety of ustekinumab in bio-naïve and bio-experienced anti-tumor necrosis factor patients with Crohn’s disease: a real-world multicenter Brazilian study
2022 · Rogério Serafim Parra, Júlio Maria Fonseca Chebli, et al. · BMC Gastroenterology · 26
PDF
Effectiveness and Safety of Ustekinumab for Ulcerative Colitis: A Brazilian Multicentric Observational Study
2024 · Rogério Serafim Parra, Júlio Maria Fonseca Chebli, et al. · Crohn s & Colitis 360 · 11
PDF
Surgical Management of Adult Crohn’s Disease and Ulcerative Colitis Patients: a Consensus From the Brazilian Organization of Crohn’s Disease and Colitis (gediib)
2023 · Gilmara Pandolfo ZABOT, Ornella Sari CASSOL, et al. · Arquivos de Gastroenterologia · 6
PDF
Tissue content of metalloproteinase-9 and collagen in the colon with and without fecal stream after intervention with infliximab in rats subjected to Hartmann’s surgery
2021 · Antonio José Tiburcio Alves Junior, José Aires Pereira, et al. · Acta Cirúrgica Brasileira · 4
PDF
Expressão De E-caderina E Claudina-3 No Epitélio Cólico Após Terapia Com Infliximabe: Modelo Experimental De Colite De Exclusão
2021 · Antonio José Tiburcio ALVES JR, Eduardo Felipe Kim GOTO, et al. · ABCD Arquivos Brasileiros de Cirurgia Digestiva (São Paulo) · 3
PDF
P460 Efficacy of ustekinumab in patients with anti-TNF refractory Crohn’s disease: data from a real-world study in Brazil
2019 · R S Parra, M R Feitosa, et al. · Journal of Crohn s and Colitis · 3
Clinical effectiveness and safety of vedolizumab versus infliximab in biologic-naïve patients with ulcerative colitis: A comparative real-world multicentric observational study
2025 · Sandro da Costa Ferreira, Rogério Serafim Parra, et al. · Gastroenterología y Hepatología (English Edition) · 2
Tofacitinib for ulcerative colitis in Brazil: a multicenter observational study on effectiveness and safety
2025 · Rogério Serafim Parra, Renata de Sá Brito Fróes, et al. · BMC Gastroenterology · 1
Série De Casos: Tumor De Intestino Delgado
2018 · Milossi Estheisi Romero Machuca, Antonio Jose Tiburcio Alves Junior, et al. · Journal of Coloproctology · 1
Tumor Miofibroblástico Inflamatório: Relato De Caso
2018 · Hugo Samaritne Junior, Guilherme Zupo Teixeira, et al. · Journal of Coloproctology · 1
103 Prior Exposure to Biologics and its Impact on Outcomes in Ulcerative Colitis: An Integrated Analysis of a Brazilian Cohort
2025 · Rodrigo G. Gasparini, Carlos Taxonera, et al. · The American Journal of Gastroenterology
112 Real-World Comparative Effectiveness and Safety of Ustekinumab Versus Anti-TNF Agents as First- or Second-Line Biologics in Crohn’s Disease: A Multicenter Observational Study
2025 · Sandro da Costa Ferreira, Rogério Serafim Parra, et al. · The American Journal of Gastroenterology
Real-World Effectiveness and Safety of Golimumab in Patients with Ulcerative Colitis: A Retrospective Cohort Study
2025 · Rodrigo Galhardi Gasparini, Carlos Taxonera, et al. · Journal of Clinical Medicine
PDF
Linking histological healing to quality of life: real-world insights into golimumab therapy in ulcerative colitis
2025 · Rodrigo Galhardi Gasparini, Carlos Taxonera, et al. · Current Medical Research and Opinion
P1176 Low serum albumin levels are associated with higher colectomy rates in patients with moderate-to-severe ulcerative colitis on tofacitinib
2025 · R Parra PhD, R D S B Fróes, et al. · Journal of Crohn s and Colitis
P0682 Effectiveness, safety and predictors of response to vedolizumab as first- or second-line biological therapy in patients with ulcerative colitis: A real-world observational multicenter study.
2025 · S Ferreira, R Serafim Parra, et al. · Journal of Crohn s and Colitis
P0861 Comparative effectiveness and safety of ustekinumab versus anti-tumour necrosis Factor agents as first- or second-line biologics in Crohn´s disease: a real-world multicentric observational study
2025 · S Ferreira, R Serafim Parra, et al. · Journal of Crohn s and Colitis
PDF
S89 Effectiveness and Safety of Tofacitinib in the Management of Ulcerative Colitis: A Brazilian Observational Multicentric Study
2024 · Rogerio S. Parra, Renata de Sá Brito Froes, et al. · The American Journal of Gastroenterology
S26 Clinical Effectiveness and Safety of Vedolizumab Versus Infliximab in Biologic-Naïve Ulcerative Colitis Patients: A Real-World Multicentric Observational Study
2024 · Sandro da Costa Ferreira, Rogerio Serafim Parra, et al. · The American Journal of Gastroenterology
Elastic Band Ligation – Data Update
2024 · Blanca da Silva Martinez, Mariana Gonçalves Marangon, et al. · Journal of Coloproctology
PDF
Profile of Surgeons Who Treat Inflammatory Bowel Diseases in Brazil
2024 · Gilmara Pandolfo Zabot, Ornella Sari Cassol, et al. · Journal of Coloproctology
PDF
P698 Effectiveness and Safety of Ustekinumab for Ulcerative Colitis: A Brazilian Multicentre Real-World Observational Study
2024 · R Parra, J M F Chebli, et al. · Journal of Crohn s and Colitis
PDF
Tu1238 SAFETY AND EFFECTIVENESS OF USTEKINUMAB THERAPY FOR ULCERATIVE COLITIS: A BRAZILIAN MULTICENTER REAL-WORLD STUDY
2023 · Rogerio S. Parra, Matheus Azevedo, et al. · Gastroenterology
PDF
Correção De Retocele Com Macroligadura Elástica
2022 · Matheus de Carvalho Bassani, José Alfredo dos Reis, et al. · Journal of Coloproctology
Macroligadura Alta Na Doença Hemorroidária Interna
2022 · Matheus de Carvalho Bassani, José Alfredo dos Reis Júnior, et al. · Journal of Coloproctology
Works count: 56
Citation count: 58
H-index: 4
I10-index: 2
Year
Topic
Type